Open Access

ARTICLE

APRIL is increased in serum of patients with brain glioblastoma multiforme

Joanna Iłżecka¹, Marek Iłżecki²

1 Department of Neurology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland
2 Department of Vascular Surgery and Angiology, Medical University of Lublin, Poland

* Corresponding Author: J. Iłżecka, MD,

European Cytokine Network 2006, 17(4), 276-280. https://doi.org/10.1684/ecn.2006.0044

Abstract

A PRoliferation-Inducing Ligand (APRIL) is a cytokine with the ability to induce tumorigenesis. The aim of the study was to measure serum APRIL levels in patients with brain glioblastoma multiforme. Twenty five patients with brain tumor and a control group of 25 subjects took part in the study. APRIL was measured by the enzyme-linked immunosorbent method. The study showed increased APRIL levels in the serum of patients with brain glioblastoma multiforme compared to the control group (p < 0.05). However, there was no significant difference in the level of this cytokine between groups of patients divided according to their clinical state and tumor size (p > 0.05). Inflammation parameters such as C-reactive protein (CRP) and polymorphonuclear leucocytes (PMN) were also increased in patients with brain tumor compared to controls (p < 0.05). There was a significant correlation between APRIL and CRP and PMN (p < 0.05). Results from the study suggest that APRIL may play a role in the pathogenesis of brain glioblastoma multiforme. It is possible that anti-APRIL therapy might be useful in this disease. However, this cytokine cannot be regarded as a marker of tumor size or of severity of the clinical condition of patients.

---

Keywords

---